Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.63
(
0.43%
)
Bitcoin
80,446.42
(
-0.76%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 141649

Wednesday, 05/09/2012 4:44:39 PM

Wednesday, May 09, 2012 4:44:39 PM

Post# of 257566
Quantification of #msg-75394204 re Copaxone: According to today’s CC (near the end of the Q&A), Teva’s modified agreements with US wholesalers cost Teva $120M in 1Q12 Copaxone sales. This $120M figure almost exactly coincides to the difference between the reported 1Q12 sales of $617M and my $740M estimate of 4Q11 sales (#msg-72138967).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today